You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Question for MCGrad re: Aztreonam
- Thread starter dasjsmum
- Start date
M
MCGrad2006
Guest
You can boil the plastic parts of the eflow while the other piece is resting in rubbing alcohol. When the water is done boiling and the other pieces are done, you can rinse the metal part of the eflow in the hot...NOT BOILING...but sterile water. They recomended me to do that twice a week...but use gentle soap after every use.
M
MCGrad2006
Guest
You can boil the plastic parts of the eflow while the other piece is resting in rubbing alcohol. When the water is done boiling and the other pieces are done, you can rinse the metal part of the eflow in the hot...NOT BOILING...but sterile water. They recomended me to do that twice a week...but use gentle soap after every use.
M
MCGrad2006
Guest
You can boil the plastic parts of the eflow while the other piece is resting in rubbing alcohol. When the water is done boiling and the other pieces are done, you can rinse the metal part of the eflow in the hot...NOT BOILING...but sterile water. They recomended me to do that twice a week...but use gentle soap after every use.
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
a couple of months ago i was involved with a marketing research study for the eFlow delivery of aztreonam. i wrote about it in my blog. of course it is good news that new drugs and products for cystic fibrosis are coming out. but the whole thing really left a bad taste in my mouth.
<a target=_blank class=ftalternatingbarlinklarge href="http://blogs.cysticfibrosis.com/blogpost.cfm?threadid=14622&catid=191">my blog on the eFlow experiment</a>
a couple of other things: as for the increased effectiveness on the delivery b/c of smaller particle size...i'm wondering about how this fits in with something my doctor was saying at my last visit. he said that some CF doctors believe that our bugs mostly live in the upper lobes of our lungs and migrate downward only when irritated by a virus or another disturbance in the lungs. [or from pulmozyme, warwick might say!]
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
just throwing some stuff out there.
a couple of months ago i was involved with a marketing research study for the eFlow delivery of aztreonam. i wrote about it in my blog. of course it is good news that new drugs and products for cystic fibrosis are coming out. but the whole thing really left a bad taste in my mouth.
<a target=_blank class=ftalternatingbarlinklarge href="http://blogs.cysticfibrosis.com/blogpost.cfm?threadid=14622&catid=191">my blog on the eFlow experiment</a>
a couple of other things: as for the increased effectiveness on the delivery b/c of smaller particle size...i'm wondering about how this fits in with something my doctor was saying at my last visit. he said that some CF doctors believe that our bugs mostly live in the upper lobes of our lungs and migrate downward only when irritated by a virus or another disturbance in the lungs. [or from pulmozyme, warwick might say!]
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
just throwing some stuff out there.
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
a couple of months ago i was involved with a marketing research study for the eFlow delivery of aztreonam. i wrote about it in my blog. of course it is good news that new drugs and products for cystic fibrosis are coming out. but the whole thing really left a bad taste in my mouth.
<a target=_blank class=ftalternatingbarlinklarge href="http://blogs.cysticfibrosis.com/blogpost.cfm?threadid=14622&catid=191">my blog on the eFlow experiment</a>
a couple of other things: as for the increased effectiveness on the delivery b/c of smaller particle size...i'm wondering about how this fits in with something my doctor was saying at my last visit. he said that some CF doctors believe that our bugs mostly live in the upper lobes of our lungs and migrate downward only when irritated by a virus or another disturbance in the lungs. [or from pulmozyme, warwick might say!]
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
just throwing some stuff out there.
a couple of months ago i was involved with a marketing research study for the eFlow delivery of aztreonam. i wrote about it in my blog. of course it is good news that new drugs and products for cystic fibrosis are coming out. but the whole thing really left a bad taste in my mouth.
<a target=_blank class=ftalternatingbarlinklarge href="http://blogs.cysticfibrosis.com/blogpost.cfm?threadid=14622&catid=191">my blog on the eFlow experiment</a>
a couple of other things: as for the increased effectiveness on the delivery b/c of smaller particle size...i'm wondering about how this fits in with something my doctor was saying at my last visit. he said that some CF doctors believe that our bugs mostly live in the upper lobes of our lungs and migrate downward only when irritated by a virus or another disturbance in the lungs. [or from pulmozyme, warwick might say!]
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
just throwing some stuff out there.
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
a couple of months ago i was involved with a marketing research study for the eFlow delivery of aztreonam. i wrote about it in my blog. of course it is good news that new drugs and products for cystic fibrosis are coming out. but the whole thing really left a bad taste in my mouth.
<a target=_blank class=ftalternatingbarlinklarge href="http://blogs.cysticfibrosis.com/blogpost.cfm?threadid=14622&catid=191">my blog on the eFlow experiment</a>
a couple of other things: as for the increased effectiveness on the delivery b/c of smaller particle size...i'm wondering about how this fits in with something my doctor was saying at my last visit. he said that some CF doctors believe that our bugs mostly live in the upper lobes of our lungs and migrate downward only when irritated by a virus or another disturbance in the lungs. [or from pulmozyme, warwick might say!]
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
just throwing some stuff out there.
a couple of months ago i was involved with a marketing research study for the eFlow delivery of aztreonam. i wrote about it in my blog. of course it is good news that new drugs and products for cystic fibrosis are coming out. but the whole thing really left a bad taste in my mouth.
<a target=_blank class=ftalternatingbarlinklarge href="http://blogs.cysticfibrosis.com/blogpost.cfm?threadid=14622&catid=191">my blog on the eFlow experiment</a>
a couple of other things: as for the increased effectiveness on the delivery b/c of smaller particle size...i'm wondering about how this fits in with something my doctor was saying at my last visit. he said that some CF doctors believe that our bugs mostly live in the upper lobes of our lungs and migrate downward only when irritated by a virus or another disturbance in the lungs. [or from pulmozyme, warwick might say!]
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
just throwing some stuff out there.
chantelfox
New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>catboogie</b></i>
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
.</end quote></div>
Yeah, I noticed this.....<img src="i/expressions/face-icon-small-sad.gif" border="0">
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
.</end quote></div>
Yeah, I noticed this.....<img src="i/expressions/face-icon-small-sad.gif" border="0">
chantelfox
New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>catboogie</b></i>
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
.</end quote></div>
Yeah, I noticed this.....<img src="i/expressions/face-icon-small-sad.gif" border="0">
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
.</end quote></div>
Yeah, I noticed this.....<img src="i/expressions/face-icon-small-sad.gif" border="0">
chantelfox
New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>catboogie</b></i>
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
.</end quote></div>
Yeah, I noticed this.....<img src="i/expressions/face-icon-small-sad.gif" border="0">
lol--it has just occurred to me reading this thread that the time saved on medicine delivery with the eflow is replaced by cleaning time! (i'm not sure how good of a trade-off that is.)
.</end quote></div>
Yeah, I noticed this.....<img src="i/expressions/face-icon-small-sad.gif" border="0">
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>catboogie</b></i>
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
</end quote></div>
it's the exact opposite. TOBI is one month on, one month off to reduce propensity to induce resistance.
the more bacteria are exposed to an antibiotic, the more likely resistance will develop.
so if you continually expose PA to TOBI, the bacteria that will survive despite TOBI exposure will be those who have a mutation that allow them to survive TOBI exposure. What's left? A bunch of PA that's resistant to TOBI. Obviously this process occures over multiple antibiotic exposures, but no matter what the drug or what the bacteria, resistance develops. always has. always will.
explain your logic to me of how being off an antibiotic will induce resistance?
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
</end quote></div>
it's the exact opposite. TOBI is one month on, one month off to reduce propensity to induce resistance.
the more bacteria are exposed to an antibiotic, the more likely resistance will develop.
so if you continually expose PA to TOBI, the bacteria that will survive despite TOBI exposure will be those who have a mutation that allow them to survive TOBI exposure. What's left? A bunch of PA that's resistant to TOBI. Obviously this process occures over multiple antibiotic exposures, but no matter what the drug or what the bacteria, resistance develops. always has. always will.
explain your logic to me of how being off an antibiotic will induce resistance?
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>catboogie</b></i>
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
</end quote></div>
it's the exact opposite. TOBI is one month on, one month off to reduce propensity to induce resistance.
the more bacteria are exposed to an antibiotic, the more likely resistance will develop.
so if you continually expose PA to TOBI, the bacteria that will survive despite TOBI exposure will be those who have a mutation that allow them to survive TOBI exposure. What's left? A bunch of PA that's resistant to TOBI. Obviously this process occures over multiple antibiotic exposures, but no matter what the drug or what the bacteria, resistance develops. always has. always will.
explain your logic to me of how being off an antibiotic will induce resistance?
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
</end quote></div>
it's the exact opposite. TOBI is one month on, one month off to reduce propensity to induce resistance.
the more bacteria are exposed to an antibiotic, the more likely resistance will develop.
so if you continually expose PA to TOBI, the bacteria that will survive despite TOBI exposure will be those who have a mutation that allow them to survive TOBI exposure. What's left? A bunch of PA that's resistant to TOBI. Obviously this process occures over multiple antibiotic exposures, but no matter what the drug or what the bacteria, resistance develops. always has. always will.
explain your logic to me of how being off an antibiotic will induce resistance?
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>catboogie</b></i>
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
</end quote></div>
it's the exact opposite. TOBI is one month on, one month off to reduce propensity to induce resistance.
the more bacteria are exposed to an antibiotic, the more likely resistance will develop.
so if you continually expose PA to TOBI, the bacteria that will survive despite TOBI exposure will be those who have a mutation that allow them to survive TOBI exposure. What's left? A bunch of PA that's resistant to TOBI. Obviously this process occures over multiple antibiotic exposures, but no matter what the drug or what the bacteria, resistance develops. always has. always will.
explain your logic to me of how being off an antibiotic will induce resistance?
next: is it not true that the only reason that Tobi was put to market as a month-on, month-off drug was because it was originally tested along with another inhaled antibiotic for the off-tobi-month that never made it to market? (i honestly do not know this for a fact.) i guess i'm saying that some doctors don't think that schedule is a good idea b/c it will allow for resistance with that stoppage period. and i'm wondering why, if it might be less than optimal to curb resistance, that is now the pattern that the aztreonam study is following?
</end quote></div>
it's the exact opposite. TOBI is one month on, one month off to reduce propensity to induce resistance.
the more bacteria are exposed to an antibiotic, the more likely resistance will develop.
so if you continually expose PA to TOBI, the bacteria that will survive despite TOBI exposure will be those who have a mutation that allow them to survive TOBI exposure. What's left? A bunch of PA that's resistant to TOBI. Obviously this process occures over multiple antibiotic exposures, but no matter what the drug or what the bacteria, resistance develops. always has. always will.
explain your logic to me of how being off an antibiotic will induce resistance?